Please login to the form below
RG3039
This page shows the latest RG3039 news and features for those working in and with pharma, biotech and healthcare.
Pfizer acquires spinal muscular atrophy research programme
Gains rights to drug candidate RG3039 in deal with Repligen that could be worth up to $70m. ... $5m. The main candidate involved in the programme is RG3039, which will undergo phase I trials carried out by Repligen in the first quarter of 2013.
Latest news
More from news
Approximately 1 fully matching, plus 0 partially matching documents found.
Latest Intelligence
-
Pharma deals during January 2013
This programme includes RG3039, a small molecule drug candidate in clinical development, as well as backup compounds and enabling technologies. ... Licence. RG3039 orphan for spinal muscular atrophy. 70. Amplimmune / Daiichi Sankyo.
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Senior Account Director development role to Business Director, H...
-
Excellent package
- Editorial Assistant Medical Education Agency
-
£25, 000 - £26, 000
-
Account Director, Medical Education
-
Salary TBC
- Global Business Development Director – Health Education
-
excellent commission
-
Associate Director
-
£75, 000-90, 000
-
Medical Writer
-
Salary TBC
-
Account Director
-
Competitive Salary Offered
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Account Manager / Account Director
-
Competative
- Senior Account Manager, Rare Diseases – Medical Communications, ...
-
Excellent package
- Account Manager / Senior Account Manager
-
35, 000-40, 000
- Engagement Expert, Healthcare Brand Communications, London
-
Excellent package
-
Senior Medical Writer
-
Salary TBC
-
Business Director
-
Competitive Salary Offered
-
Senior Account Manager
-
Competitive Salary Offered
Subscribe to our email news alerts
- Meet Porterhouse Medical at the ISMPP EU meeting 2019 in London 22 - 23 January
- Immunomedics craters after FDA rejects breast cancer ADC
- UK businesses leaning towards second Brexit vote
- NHS England sees off AbbVie's Hep C legal challenge
- China’s clinical trial shake-up
- Europe closer to biosimilar rule change, despite fierce resistance from pharma
PMHub
Atlantis Healthcare
Atlantis Healthcare is a global leader in optimising patient self-management. Established in 1996, we design, develop and implement scalable solutions...
Latest intelligence
- China’s clinical trial shake-up
- As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
- Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
- Healthcare leaders in the European Union should begin preparing for a breakthrough now...
- The UK’s new five-year pricing agreement
- Pharma has agreed to capped growth again - in exchange for uptake promises...
Quick links
Infographics
